GSK 0001654954-26-007560 6-K Filing: Aug 13, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the ‘Company’)

Transaction notification

1.	Details of PDMR/person closely associated with them<br>(‘PCA’)
a)	Name	Lynn Baxter
b)	Position/status	President, Europe
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary<br>Shares’)<br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares under the Company’s Share<br>Reward Plan
c)	Price(s)<br>and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated<br>information
	Aggregated<br>volume Price	14 Ordinary Shares<br><br><br>£19.3496
e)	Date<br>of the transaction	2026-08-11
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>(‘PCA’)
---	---	---	---
a)	Name	Julie Brown
b)	Position/status	Chief<br>Financial Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary<br>Shares’)<br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares under the Company’s Share<br>Reward Plan
c)	Price(s)<br>and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated<br>information
	Aggregated<br>volume Price	14 Ordinary Shares<br><br><br>£19.3496
e)	Date<br>of the transaction	2026-08-11
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>(‘PCA’)
---	---	---	---
a)	Name	James Ford
b)	Position/status	SVP and<br>Group General Counsel, Legal and Compliance
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary<br>Shares’)<br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares under the Company’s Share<br>Reward Plan
c)	Price(s)<br>and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated<br>information
	Aggregated<br>volume Price	14 Ordinary Shares<br><br><br>£19.3496
e)	Date<br>of the transaction	2026-08-11
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>(‘PCA’)
---	---	---	---
a)	Name	David Redfern
b)	Position/status	President,<br>Corporate Development
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary<br>Shares’)<br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares under the Company’s Share<br>Reward Plan
c)	Price(s)<br>and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated<br>information
	Aggregated<br>volume Price	14 Ordinary Shares<br><br><br>£19.3496
e)	Date<br>of the transaction	2026-08-11
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>(‘PCA’)
---	---	---	---
a)	Name	Regis Simard
b)	Position/status	President,<br>Global Supply Chain
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary<br>Shares’)<br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares under the Company’s Share<br>Reward Plan
c)	Price(s)<br>and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated<br>information
	Aggregated<br>volume Price	14 Ordinary Shares<br><br><br>£19.3496
e)	Date<br>of the transaction	2026-08-11
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>(‘PCA’)
---	---	---	---
a)	Name	Philip Thomson
b)	Position/status	President,<br>Global Affairs
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary<br>Shares’)<br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares under the Company’s Share<br>Reward Plan
c)	Price(s)<br>and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated<br>information
	Aggregated<br>volume Price	14 Ordinary Shares<br><br><br>£19.3496
e)	Date<br>of the transaction	2026-08-11
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>(‘PCA’)
---	---	---	---
a)	Name	Deborah Waterhouse
b)	Position/status	CEO,<br>ViiV Healthcare and President, Global Health, GSK
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary<br>Shares’)<br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares under the Company’s Share<br>Reward Plan
c)	Price(s)<br>and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated<br>information
	Aggregated<br>volume Price	14 Ordinary Shares<br><br><br>£19.3496
e)	Date<br>of the transaction	2026-08-11
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>(‘PCA’)
---	---	---	---
a)	Name	Victoria Whyte
b)	Position/status	SVP<br>& Company Secretary
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary<br>Shares’)<br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares under the Company’s Share<br>Reward Plan
c)	Price(s)<br>and volume(s)	Price(s)	Volume(s)
		£19.3496	6 (partnership shares)
		£19.3496	6 (matching shares)
d)	Aggregated<br>information
	Aggregated<br>volume Price	12 Ordinary Shares<br><br><br>£19.3496
e)	Date<br>of the transaction	2026-08-11
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>(‘PCA’)
---	---	---	---
a)	Name	Neil Falkingham
b)	Position/status	PCA of Lynn Baxter (President, Europe)
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary<br>Shares’)<br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Acquisition of Ordinary Shares under the Company’s Share<br>Reward Plan
c)	Price(s)<br>and volume(s)	Price(s)	Volume(s)
		£19.3496	7 (partnership shares)
		£19.3496	7 (matching shares)
d)	Aggregated<br>information
	Aggregated<br>volume Price	14 Ordinary Shares<br><br><br>£19.3496
e)	Date<br>of the transaction	2026-08-11
f)	Place<br>of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: August<br>13, 2026

	By:/s/ VICTORIA<br>WHYTE<br><br>--------------------------

	Victoria Whyte
	Authorised<br>Signatory for and on
	behalf<br>of GSK plc

GSK 6-K